CVS caremark™ {{PANUMCODE}}

Stelara

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}} **Date**: {{TODAY}}
Patient's ID: {{MEMBERID}} **Patient's Date of Birth:** {{MEMBERDOB}}
Physician's Name: {{PHYFIRST}} {{PHYLAST}}
Specialty: _____, **NPI#:** _____
Physician Office Telephone: {{PHYSICIANPHONE}} **Physician Office Fax:** {{PHYSICIANFAX}}
Request Initiated For: {{DRUGNAME}}

1. What is the prescribed dose and frequency?
   a) **Loading dose:**
   - ❑ Stelara SQ 45 mg Quantity and Frequency: _____
   - ❑ Stelara SQ 90 mg Quantity and Frequency: _____
   - ❑ Stelara IV Quantity and Frequency: _____
   - ❑ Other _____

   b) **Maintenance dose:**
   - ❑ Stelara SQ 45 mg Quantity and Frequency: _____
   - ❑ Stelara SQ 90 mg Quantity and Frequency: _____
   - ❑ Stelara IV Quantity and Frequency: _____
   - ❑ Other _____

2. What is the diagnosis?
   - ❑ Moderate to severe plaque psoriasis (PsO)
   - ❑ Active psoriatic arthritis WITH co-existent plaque psoriasis (PsA)
   - ❑ Moderately to severely active Crohn's disease (CD)
   - ❑ Moderately to severely active ulcerative colitis (UC)
   - ❑ Active psoriatic arthritis WITHOUT co-existent plaque psoriasis (PsA)
   - ❑ Other _____

3. What is the ICD-10 code? _____ Patient's weight: _____ kg / lbs ***(circle one)***

Section A: Preferred Product

4. These are the preferred products for which coverage is provided for the treatment of the following indications:
   a) Crohn's disease: **Humira, Remicade, Stelara (IV)**
   b) Ulcerative colitis: **Humira, Remicade, Stelara (IV)**
   Can the patient's treatment be switched to a preferred product?
   ❑ Yes - Please specify: _____ ***If Yes, please call 1-866-814-5506 to have the updated form faxed to your office OR you may complete the PA electronically (ePA). You may sign up online via CoverMyMeds at: www.covermymeds.com/epa/caremark/ or call 1-866-452-5017.***
   ❑ No ❑ Not applicable - Requested for condition not listed above, *skip to Section B: All Requests*

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

5. Is this request for continuation of therapy with the requested product? ❑ Yes ❑ No *If No, skip to #7*

6. Is the patient currently receiving the requested product through samples or a manufacturer's patient assistance program? If unknown, answer Yes. ❑ Yes ❑ No *If No, skip to Section B: All Requests.*

7. Does the patient have a documented inadequate response or intolerable adverse event to Humira?
ACTION REQUIRED: If Yes, attach supporting chart note(s). ❑ Yes ❑ No

8. Does the patient have one of the following documented clinical reasons to avoid the preferred products that are TNF inhibitors (Humira)? ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***
❑ Yes - History of demyelinating disorder - *Indicate drug(s):* _____
❑ Yes - History of congestive heart failure- *Indicate drug(s):* _____
❑ Yes - History of hepatitis B virus infection- *Indicate drug(s):* _____
❑ Yes - Autoantibody formation/lupus-like syndrome (attributed to TNF inhibitor)
Indicate drug(s): _____
❑ Yes - Risk of lymphoma- *Indicate drug(s):* _____
❑ No - none of the above
❑ Not applicable - requested medication is a TNF inhibitor

Section B: All Requests

9. Will the requested drug be used in combination with any other biologic (e.g., Humira) or targeted synthetic drug (e.g., Olumiant, Otezla, Xeljanz)? ❑ Yes ❑ No

10. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic DMARD (e.g., Olumiant, Xeljanz) associated with an increased risk of tuberculosis? *If Yes, skip to #12* ❑ Yes ❑ No

11. Has the patient had a tuberculosis (TB) test (e.g., tuberculosis skin test [PPD], interferon-release assay [IGRA], chest x-ray) within 6 months of initiating therapy? *If Yes, skip to #14* ❑ Yes ❑ No

12. Does the patient have risk factors for tuberculosis (TB) (e.g., persons with close contact to people with infectious TB disease; persons who have recently immigrated from areas of the world with high rates of TB [e.g., Africa, Asia, Eastern Europe, Latin America, Russia]; children less than 5 years of age who have a positive TB test; groups with high rates of TB transmission [e.g., homeless persons, injection drug users, persons with HIV infection], or persons who work or reside with people who are at an increased risk for active TB [e.g., hospitals, long-term care facilities, correctional facilities, homeless shelters])? ❑ Yes ❑ No *If No, skip to #17*

13. Has the patient been tested for tuberculosis (TB) within the previous 12 months? ❑ Yes ❑ No

14. What were the results of the TB test?
❑ Positive for TB ❑ Negative for TB, *skip to #17* ❑ Unknown

15. Does the patient have latent or active tuberculosis (TB)? ❑ Latent ❑ Active ❑ Unknown

16. Has treatment for latent tuberculosis (TB) infection been initiated or completed?
❑ Yes - treatment initiated ❑ Yes - treatment completed ❑ No

17. Is the patient currently receiving Stelara? ❑ Yes ❑ No

18. Is this request for continuation of therapy with the requested drug?
❑ Yes ❑ No *If No, skip to diagnosis section*

19. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program? *If Yes or Unknown, skip to diagnosis section* ❑ Yes ❑ No ❑ Unknown

20. Has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition since starting treatment with the requested drug?
❑ Yes ❑ No

Complete the following section based on the patient's diagnosis, if applicable.

Section C: Plaque Psoriasis

21. Has the patient been diagnosed with coexistent psoriatic arthritis? *If Yes, skip to Section D* ❑ Yes ❑ No

22. Is the requested drug prescribed by or in consultation with a dermatologist? ❑ Yes ❑ No

23. Is the patient currently receiving therapy with the requested drug? *If Yes, skip to #29* ❑ Yes ❑ No

Initiation

24. Has the patient ever received (including current utilizers) Otezla or a biologic (e.g., Humira) indicated for the treatment of moderate to severe plaque psoriasis? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried and no further questions.*** ❑ Yes ❑ No

25. Are crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) affected? ***ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation of affected areas and body surface area affected and no further questions.*** ❑ Yes ❑ No

26. What is the percentage of body surface area (BSA) affected (prior to starting the requested medication)? _____ % ***ACTION REQUIRED: Please attach chart notes or medical record documentation of affected areas and body surface area affected.*** *If greater than or equal to 10% of BSA, no further questions*

27. Has the patient experienced an inadequate response, or has an intolerance to phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine or acitretin? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.*** ❑ Yes ❑ No

28. Does the patient have a clinical reason to avoid pharmacologic treatment with methotrexate, cyclosporine and acitretin? ***ACTION REQUIRED: If Yes, please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No ***If Yes, indicate clinical reason:*** _____

Continuation

29. Has the patient experienced a reduction in body surface area (BSA) affected from baseline? ***ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation of decreased body surface area affected.*** ❑ Yes ❑ No

30. Has the patient experienced an improvement in signs and symptoms of the condition from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)? ***ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation of improvement in signs and symptoms*** ❑ Yes ❑ No

Section D: Psoriatic Arthritis - (*complete this section and Section E if applicable)*

Continuation

31. Which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response.***
    - ❑ Number of swollen joints
    - ❑ Number of tender joints
    - ❑ Dactylitis
    - ❑ Enthesitis
    - ❑ Skin and/or nail involvement
    - ❑ None of the above

Section E: Psoriatic Arthritis WITH Co-Existent Plaque Psoriasis

32. Has the patient ever received (including current utilizers) Otezla or a biologic (e.g., Humira) indicated for the treatment of moderate to severe plaque psoriasis? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried and no further questions.*** ❑ Yes ❑ No *If request is for continuation of therapy, no further questions*

33. Are crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) affected? ***ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation of affected areas and body surface area affected and no further questions.*** ❑ Yes ❑ No

34. What is the patient's psoriasis involvement in body surface area (BSA) percent (prior to starting the requested medication)? _____ % ***ACTION REQUIRED: Please attach chart notes or medical record documentation of affected area and body surface area affected.*** *If greater than or equal to 10%, no further questions*

35. Has the patient experienced an inadequate response, or has an intolerance to phototherapy (e.g., UVB, PUVA) or pharmacologic treatment with methotrexate, cyclosporine or acitretin? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy and no further questions.*** ❑ Yes ❑ No

36. ***ACTION REQUIRED: If Yes, please attach documentation of clinical reason to avoid therapy.***
❑ Yes ❑ No ***If Yes, indicate clinical reason:*** _____

Section F: Crohn's Disease

Continuation

37. Has the patient achieved or maintained remission? ***ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation of remission and no further questions.*** ❑ Yes ❑ No

38. Which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response and no further questions.***
❑ Abdominal pain or tenderness ❑ Diarrhea ❑ Body weight
❑ Abdominal mass ❑ Hematocrit ❑ Endoscopic appearance of the mucosa
❑ Improvement on a disease activity scoring tool (e.g., Crohn's Disease Activity Index (CDAI) score
❑ None of the above

Initiation

39. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) indicated for Crohn's disease? ***ACTION REQUIRED: If Yes, attach chart notes, medical record documentation, or claims history supporting previous medications tried and no further questions.*** ❑ Yes ❑ No

40. Has the patient tried and had an inadequate response to at least one conventional therapy option? ***ACTION REQUIRED: If Yes, indicate below, attach patient's chart notes, medical record documentation, or claims history of previous medications tried, including response to therapy and no further questions.***
List continues on next page.
❑ Yes - Sulfasalazine (Azulfidine, Sulfazine) ❑ Yes - Metronidazole (Flagyl)
❑ Yes - Ciprofloxacin (Cipro) ❑ Yes - Prednisone
❑ Yes - Budesonide (Entocort EC) ❑ Yes - Azathioprine (Azasan, Imuran)
❑ Yes - Mercaptopurine (Purinethol) ❑ Yes - Methylprednisolone (Solu-Medrol)
❑ Yes - Methotrexate intramuscular (IM) or subcutaneous (SC) ❑ Yes - Rifaximin (Xifaxan)
❑ Yes - Tacrolimus ❑ No

41. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], budesonide [Entocort EC], ciprofloxacin [Cipro], mercaptopurine [Purinethol], methylprednisolone [Solu-Medrol], methotrexate, metronidazole [Flagyl], prednisone, sulfasalazine [Azulfidine, Sulfazine], rifaximin [Xifaxan], tacrolimus)? ***ACTION REQUIRED: If Yes, attach chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy. If therapy is if not advisable, please attach documentation of clinical reason to avoid therapy.*** ❑ Yes ❑ No

Section G: Ulcerative Colitis

Continuation

42. Has the patient achieved or maintained remission? ***ACTION REQUIRED: If Yes, please attach chart notes or medical record documentation of remission.*** ❑ Yes ❑ No

43. Which of the following has the patient experienced an improvement in from baseline? ***ACTION REQUIRED: Please attach chart notes or medical record documentation supporting positive clinical response and no further questions.***
❑ Stool frequency ❑ Rectal bleeding ❑ Urgency of defecation
❑ C-reactive protein (CRP) ❑ Fecal calprotectin (FC) ❑ Endoscopic appearance of the mucosa
❑ Improvement on a disease activity scoring tool (e.g., Ulcerative colitis Endoscopic Index of Severity [UCEIS], Mayo Score)
❑ None of the above

Initiation

44. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic drug (e.g., Xeljanz) indicated for moderately to severely active ulcerative colitis? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried and no further questions.*** ❑ Yes ❑ No

45. Has the patient tried and had an inadequate response to at least one conventional therapy option? ***ACTION REQUIRED: If Yes, indicate below, attach patient's chart notes, medical record documentation, or claims history of previous medications tried, including response to therapy, and no further questions.***
    ❑ Yes - Azathioprine (Azasan, Imuran)
    ❑ Yes - Sulfasalazine
    ❑ Yes - Cyclosporine (Sandimmune)
    ❑ Yes - Tacrolimus (Prograf)
    ❑ Yes - Mercaptopurine (Purinethol)
    ❑ Yes - Mesalamine (e.g., Asacol, Lialda, Pentasa, Canasa, Rowasa), balsalazide, olsalazine
    ❑ Yes - Corticosteroid (hydrocortisone [Cortifoam, Colocort, Solu-Cortef, Cortef], methylprednisolone [Medrol, Solu-Medrol], prednisone)
    ❑ No

46. Does the patient have a contraindication or intolerance to at least one conventional therapy option (e.g., azathioprine [Azasan, Imuran], corticosteroid [e.g., hydrocortisone, methylprednisolone, prednisone, cyclosporine [Sandimmune], mesalamine [Asacol, Lialda, Pentasa, Canasa, Rowasa], balsalazide, olsalazine, mercaptopurine [Purinethol], sulfasalazine, tacrolimus [Prograf]? ***ACTION REQUIRED: If Yes, please attach chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including clinical reason to avoid therapy.*** ❑ Yes ❑ No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155